KarXT

Afzender	Pauline Dinkelberg
Ontvanger	investor.relations@bms.com, info@karunatx.com
Antwoord-aan	pauline@verenigingafbouwmedicatie.nl
Datum	2024-09-29 15:16

Overzicht Headers Platte tekst

Good morning,

We are a Patient Association Tapering Medication in the Netherlands, working all day-everyday to help patients and their caregivers to come off psychoative medication in a safe way. All voluntary and deliberately non-subsidized to maintain independant.

One the largest obstacles in doing so is the absence of registrated lower doses to make gradually, hyperbolic reductions possible.

We see patients with protracted withdrawal syndomes caused by coming off too fast. One of them died recently through euthanasia, because the acathisia was unbearable.

https://www.madinamerica.com/2024/03/post-acute-withdrawal-syndrome-paws-how-the-last-step-to-recovery-became-the-final-step-in-life/

This is far from a new phenomia and the expectation that farmaceutical companies take their resposibility by producing lower doses before they introduce a new medication is a logical consequence.

We hope you can assure us that lower doses will be available right from the start.

Besides this we wonder:

- how long are participants in the research for approval been followed?

- has tapering been tested?

- after how many weeks of use?

Looking forward to your answers! Thank you in advance,

--

Met vriendelijke groet, kind regards,

Pauline Dinkelberg, chairperson